Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael D. West
AddedMar 31, 2024
UpdatedMay 31, 2026
Michael D. West

Michael D. West

Co-Founder, Lineage Cell Therapeutics

CrunchbaseLinkedIn

Michael D. West's Career

Lineage Cell Therapeutics
Lineage Cell Therapeutics

Carlsbad, CA, US

Co-Founder
AgeX Therapeutics
AgeX Therapeutics

Alameda, CA, US

Founder
Geron
Geron

Menlo Park, CA, US

Founder
ReCyte Therapeutics
ReCyte Therapeutics

Alameda, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael D. West's Career

Lineage Cell Therapeutics
Lineage Cell Therapeutics
Public$115.3M551990Carlsbad, CA, US
Co-Founder

Leadership at Lineage Cell Therapeutics

Stephen FarrellStephen FarrellBoard Member
Hal SternbergHal SternbergCo-Founder
Michael MulroyMichael MulroyBoard Member
Paul SegallPaul SegallCo-Founder
Judith SegallJudith SegallCo-Founder
Alfred Dennis KingsleyAlfred Dennis KingsleyBoard Member

Similar to Lineage Cell Therapeutics

CelularityCelularityFlorham Park, NJ, USCell Therapiesest. 2016CelularityFlorham Park, NJ, US · est. 2016

Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.

Public · $400M225
Legend BiotechLegend BiotechPiscataway, NJ, USCell Therapiesest. 2014Legend BiotechPiscataway, NJ, US · est. 2014

Legend Biotech: A global biopharmaceutical firm innovating cell-based therapies for life-threatening diseases.

Public · $750.5M1k
Cell Care TherapeuticsCell Care TherapeuticsMonrovia, CA, USBiopharmaceuticalsest. 2014Cell Care TherapeuticsMonrovia, CA, US · est. 2014

Cell Care Therapeutics: A California-based biopharmaceutical firm specializing in regenerative immunotherapies.

Seed · $5.3M7
Platelet BioGenesisPlatelet BioGenesisWatertown, MA, USCell Therapyest. 2014Platelet BioGenesisWatertown, MA, US · est. 2014

US-based PlateletBio pioneers in allogeneic cell therapy, innovating superior solutions for unmet medical challenges.

Series B · $132.1M39
AgeX Therapeutics
AgeX Therapeutics
Public$99.8M52017Alameda, CA, US
Founder

Leadership at AgeX Therapeutics

Gregory BaileyGregory BaileyBoard Member
Dr. Joanne M. Hackett Ph.D.Dr. Joanne M. Hackett Ph.D.Board Member
Dr Michael H MayDr Michael H MayBoard Member
Dr Joanne M HackettDr Joanne M HackettCEO

Similar to AgeX Therapeutics

LongeveronLongeveronMiami, FL, USCellular Therapiesest. 2014LongeveronMiami, FL, US · est. 2014

Longeveron Inc., a clinical-stage biotech firm, develops cellular therapies for aging-related and life-threatening conditions globally.

Public · $15.4M11
Retro BiosciencesRetro BiosciencesSan Francisco, CA, USTherapeuticsest. 2021Retro BiosciencesSan Francisco, CA, US · est. 2021

Retro Biosciences, an American medical firm, pioneers in cellular reprogramming and plasma-inspired therapeutics.

Late Stage Private · $180M44
Altos LabsAltos LabsRedwood City, CA, USCell TherapiesAltos LabsRedwood City, CA, US

Altos Labs, Inc.: An American biotech firm pioneering life extension therapies via specialized cell therapies since 2022.

Series A · $3B500
Rejuveron Life SciencesRejuveron Life SciencesSchlieren, Zürich, CHDrug Development, Therapiesest. 2019Rejuveron Life SciencesSchlieren, Zürich, CH · est. 2019

Rejuveron Life Sciences: A biotech platform investing in innovative therapies for healthy aging.

Late Stage Private · $97.6M22
Geron
Geron
Public$599.5M1071990Menlo Park, CA, US
Founder

Recent news

Germ brings end-to-end encrypted messages to BlueskyStartups | TechCrunch · 2025
Germ brings end-to-end encrypted messages to BlueskyTechCrunch · 2025

Leadership at Geron

John A. ScarlettJohn A. ScarlettCEO
Hoyoung HuhHoyoung HuhBoard Member
Robert SpiegelRobert SpiegelBoard Member
Bryan LawlisBryan LawlisBoard Member
Dawn BirDawn BirBoard Member
Chip ScarlettChip ScarlettBoard Member

Similar to Geron

GenentechGenentechSouth San Francisco, CA, USBiopharmaceuticalsest. 1976GenentechSouth San Francisco, CA, US · est. 1976

Genentech, Inc.: A pioneering US biotech firm, operating as an independent subsidiary of Roche.

Public13.5k
Kyntra BioKyntra BioSan Francisco, CA, USPharmaceuticalsest. 1993Kyntra BioSan Francisco, CA, US · est. 1993

FibroGen, Inc: A global, research-based pharmaceutical company in San Francisco, innovating treatments for unmet medical needs.

Public · $188M592
MacroGenicsMacroGenicsRockville, MD, USest. 2000MacroGenicsRockville, MD, US · est. 2000

US-based MacroGenics, Inc. develops novel biologics for cancer, autoimmune disorders, and infectious diseases.

Public · $165.9M357
Gerostate AlphaGerostate AlphaNovato, CA, USPharmaceuticalsest. 2018Gerostate AlphaNovato, CA, US · est. 2018

Gerostate Alpha: A pharmaceutical company innovating in aging and age-related disease treatment.

Seed · $150k
ReCyte Therapeutics
ReCyte Therapeutics
Acquired$9.9M02007Alameda, CA, US
CEO· C-Suite · Management

Similar to ReCyte Therapeutics

RhinoCyteRhinoCyteLouisville, KY, USStem Cell Treatmentsest. 2005RhinoCyteLouisville, KY, US · est. 2005

RhinoCyte: A leading provider of stem cell treatments, offering rewarding careers and a balanced work-life.

Angel · $4.7M2
Stemedica Cell TechnologiesStemedica Cell TechnologiesSan Diego, CA, USCell Therapy, Therapeuticsest. 2005Stemedica Cell TechnologiesSan Diego, CA, US · est. 2005

Stemedica Cell Technologies: Developing and commercializing cell and protein therapies for medical needs.

Series B · $67M175
StemcyteStemcyteBaldwin Park, CA, USStem Cell Productsest. 1997StemcyteBaldwin Park, CA, US · est. 1997

US-based StemCyte Inc. provides umbilical cord blood stem cell products for life-threatening disease treatments.

Public · $2.5M750
AgeX TherapeuticsAgeX TherapeuticsAlameda, CA, USBiotechAgeX TherapeuticsAlameda, CA, US

AgeX Therapeutics, a US biotech firm, innovates in cell immortality and regenerative biology to treat aging and related diseases.

Public · $99.8M5

Michael D. West's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Michael D. West

Herbert BoyerHerbert BoyerCo-Founder · GenentechAlejandro ZaffaroniAlejandro ZaffaroniCo-Founder · BioviaMichael PowellMichael PowellFounder · Odyssey TheraJ. Keith JoungJ. Keith JoungCo-Founder · Verve TherapeuticsMichael SnyderMichael SnyderScientific Co-founder · QuinnCarlos BustamanteCarlos BustamanteCo-Founder · Arc Bio